Aigner, T., Haag, J., Martin, J
Need a complete view of the obesity and GLP-1 market
A trans-3-hexenoyl group attached to the N-terminus gives Tesamorelin significantly greater resistance to enzymatic degradation than native GHRH.nnIt is the only GHRH analog currently approved by Health Canada and the FDA, marketed under the trade name Egrifta (and the related Egrifta SV and Egrifta WR formulations) by the Canadian biopharmaceutical company Theratechnologies for HIV-associated lipodystrophy
Recommended use: Take 1 capsule 3 times per day after a meal
I mean, if you take a group of people, like you said, that are all from like the same place or the same income bracket or the same ethnicity, whatever it is, you're gonna end up with these correlations where you can't just point to the one thing and say that this is it
The honest framing we give patients is this: the real cost of unregulated BPC-157 is not the price, it is injecting something whose concentration and purity you cannot verify